Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Income from Continuing Operations for 6 consecutive years, with 22977000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 33.82% to 22977000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 129766000.0 through Dec 2025, down 2.66% year-over-year, with the annual reading at 129766000.0 for FY2025, 2.66% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 22977000.0 at TScan Therapeutics, up from 35710000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 7912000.0 in Q1 2021, with the low at 36952000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 23011950.0, with a median of 22770000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 120.91% in 2021, then soared 33.82% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 14200000.0 in 2021, then plummeted by 31.85% to 18723000.0 in 2022, then fell by 4.75% to 19613000.0 in 2023, then tumbled by 77.02% to 34719000.0 in 2024, then skyrocketed by 33.82% to 22977000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 22977000.0, 35710000.0, and 36952000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.